Since the risk of endometrial cancers is increased after tamoxifen treatment [33], but not aromatase inhibitors [34], a genital tract examination should be recommended during follow-ups for breast cancer patients being treated with tamoxifen. This evidence concerns the gene CYP19A1 and breast carcinoma.